Better Health for All

Titan Pharmaceuticals' core product, Probuphine, is a treatment for opioid use disorder.

The company generates no revenue from products with negative health outcomes, as its primary product addresses a harmful condition. However, Probuphine carries significant safety risks, including potential serious complications from insertion and removal that may lead to death, necessitating a boxed warning and a restricted REMS program. The company's product is available through the Federal Supply Schedule for over nine million VA beneficiaries, but specific pricing data is not provided, and patient assistance programs suggest potential affordability concerns. The company aims to expand access to treatment for OUD patients, including veterans and federal agencies, but lacks specific data on the percentage of vulnerable populations reached. The company provides detailed safety information, including a boxed warning, but the repeated emphasis on serious risks and the need for a restricted program suggests that while transparent, the risks are substantial. R&D expenses were $2.0 million in Q2 2020, representing 35.1% of operating expenses, and the company is developing its ProNeura® technology for other chronic conditions. The company's efforts are directed at mitigating the significant societal health externalities of opioid addiction. The company initiated a fully-virtual Probuphine® REMS training program for healthcare providers, which is a moderate level of support. During the COVID-19 pandemic, the company implemented a virtual REMS training program and utilized digital communication to mitigate impact on patient access, which is a structured crisis response. The company's focus on treating opioid use disorder inherently addresses mental health components, but no specific mental health initiatives are detailed. The company's primary focus is on treating opioid addiction, which is a form of addiction mitigation.

Fair Pay & Worker Respect

Based on the provided documents, there is insufficient evidence to assess Titan Pharmaceuticals' performance regarding fair pay and worker respect. The company currently has no significant operations, so standard metrics like living wage coverage, safety incident rates, and collective bargaining share are not applicable

, , , , . While historical data on executive compensation exists , , this is not sufficient to determine alignment with the value given the company's dormant status. Therefore, a neutral score of 0 is assigned due to the lack of relevant operational data.

Honest & Fair Business

Titan Pharmaceuticals, Inc. has a formal whistleblower hotline and online reporting available for anonymous submissions, with protection from retaliation stated in its April 2019 Code of Business Conduct and Ethics.

However, there is no evidence of independent investigation processes. The company reported one financial restatement for the quarterly period ended September 30, 2023, due to an error in accounting, resulting in a material weakness in internal control over financial reporting, specifically involving the classification of $406,000 in payments. The company's Code of Business Conduct and Ethics prohibits bribery and improper payments, but lacks clear guidance on facilitation payments and gift thresholds, and specifics on enforcement are not detailed.

Kind to Animals

The company conducts animal testing for its 'RB94 cancer therapy' in an animal model of head and neck squamous cell carcinoma (HNSCC).

However, the provided articles do not offer specific, concrete data points regarding the strength or scope of its animal testing policy, the volume of animals used, the percentage of products certified cruelty-free, the extent of non-animal testing methods employed, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare compliance, cage-free sourcing, investment in animal-free technologies, animal agriculture ethics, participation in animal-free R&D collaborations, or public policy engagement related to animal welfare.

No War, No Weapons

The provided articles consistently describe TTNP.US (Titan Pharmaceuticals, Inc.) as a biopharmaceutical company focused on developing and commercializing therapeutics for opioid use disorder and other medical conditions.

Multiple articles explicitly state that there is no data relevant to arms contracts, dual-use technology, peacebuilding investment, or other conflict-related activities for TTNP.US. One article mentions an $80 million defense contract and potential dual-use AI technology for 'TTNP.US (Titan Technologies)'; however, this entity's business activities (technology/defense) directly contradict the core business description of Titan Pharmaceuticals, Inc. (pharmaceuticals) provided in the company description and other articles. Therefore, this information is not considered applicable to Titan Pharmaceuticals, Inc. Given the overwhelming evidence that TTNP.US is a pharmaceutical company with no stated involvement in defense or military activities, and the explicit data gaps noted in multiple articles for all 'No War, No Weapons' KPIs, there is no verifiable evidence to score any of the KPIs for Titan Pharmaceuticals, Inc.

Planet-Friendly Business

The company does not have a Science Based Target Initiative (SBTi) commitment.

No other specific quantitative data related to environmental performance, such as emissions, renewable energy use, water use, or waste diversion, is available in the provided documents.

Respect for Cultures & Communities

The provided articles, including the company's Code of Business Conduct and Ethics and press releases, do not contain any specific quantitative data or concrete evidence related to Titan Pharmaceuticals, Inc.'s respect for cultures and communities. Several SEC filings were inaccessible due to throttling,

and other documents focused on general ethical conduct or product development without addressing community engagement or cultural sensitivity metrics.

Safe & Smart Tech

The company's annual report for the fiscal year ended December 31, 2023, states that no data breaches materially affected the company and no incidents of unauthorized data use were mentioned.

However, the company received a Nasdaq delisting notice due to insufficient equity and needs to implement audit committee reforms by November 2025.